{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:37:14Z","timestamp":1788280634347,"version":"build-2803163510"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Institutional funds"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cmi.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:20:12Z","timestamp":1573690812000},"page":"158-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Advances in the therapy of bacterial bloodstream infections"],"prefix":"10.1016","volume":"26","author":[{"given":"M.","family":"Giannella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.11.001_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.11.001_bib2","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2019.11.001_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.11.001_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(10)70285-1","article-title":"Clinical management of Staphylococcus aureus bacteraemia","volume":"11","author":"Thwaites","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib5","doi-asserted-by":"crossref","first-page":"ofy123","DOI":"10.1093\/ofid\/ofy123","article-title":"The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"5","author":"Miller","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib6","article-title":"A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections","author":"Miller","year":"2018","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib8","doi-asserted-by":"crossref","first-page":"ofz270","DOI":"10.1093\/ofid\/ofz270","article-title":"Comparative Effectiveness of exclusive exposure to nafcillin or oxacillin, cefazolin, piperacillin\/tazobactam, and fluoroquinolones among a national cohort of veterans with methicillin-susceptible Staphylococcus aureus bloodstream infection","volume":"6","author":"Beganovic","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000499033","article-title":"Does the beta-lactam matter? Nafcillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"63","author":"Burrelli","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2019.11.001_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2018.02.013","article-title":"A\u00a0large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia","volume":"52","author":"Davis","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2018.11.013","article-title":"Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: results of a systematic review and meta-analysis","volume":"53","author":"Lee","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib13","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib15","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","article-title":"Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a California tertiary medical center","volume":"60","author":"Pollett","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib16","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/AAC.04677-14","article-title":"Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"59","author":"Rao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/bcp.13554","article-title":"Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia","volume":"84","author":"Rindone","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2019.11.001_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib20","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib22","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin mic in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib23","doi-asserted-by":"crossref","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2019.11.001_bib24","first-page":"61","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2019.11.001_bib27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib28","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.000749","article-title":"Can dalbavancin be used as a catheter lock solution?","author":"Diaz-Ruiz","year":"2018","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.cmi.2019.11.001_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12879-014-0687-9","article-title":"Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib32","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02216-16","article-title":"Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant enterococcus faecium bacteremia","volume":"61","author":"Britt","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib35","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib36","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib37","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib38","doi-asserted-by":"crossref","first-page":"890 e1","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib39","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute","author":"Satlin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.cmi.2019.11.001_bib40","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/cid\/ciz018","article-title":"Impact of beta-lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: a propensity score-matched analysis","volume":"69","author":"Grillo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib41","doi-asserted-by":"crossref","first-page":"406 e1","DOI":"10.1016\/j.cmi.2016.08.026","article-title":"Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia\u2014a post hoc analysis in 964 prospectively evaluated patients","volume":"23","author":"Rieg","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2019.11.001_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus Bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib44","series-title":"Combination antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia: the CAMERA2 randomised controlled trial [Abstract L0014]","author":"Davis","year":"2019"},{"key":"10.1016\/j.cmi.2019.11.001_bib45","article-title":"Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","author":"Jorgensen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib47","series-title":"Daptomycin plus fosfomycin versus daptomycin monotherapy for methicillin-resistant Staphylococcus aureus bacteremia. a multicenter, randomized, clinical trial","author":"Pujol","year":"2018"},{"key":"10.1016\/j.cmi.2019.11.001_bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-018-1122-8","article-title":"Management of bloodstream infections by infection specialists in France and Germany: a cross-sectional survey","volume":"46","author":"Diallo","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2019.11.001_bib49","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijantimicag.2017.12.010","article-title":"Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey","volume":"51","author":"Diallo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/cid\/ciu872","article-title":"The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia","volume":"60","author":"Bouza","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib51","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jac\/dkv007","article-title":"J.\u00a0beta-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium","volume":"70","author":"Smith","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib52","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41598-018-19986-8","article-title":"A\u00a0retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections","volume":"8","author":"Chuang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2019.11.001_bib53","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/AAC.02274-13","article-title":"Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium","volume":"58","author":"Sakoulas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jac\/dku386","article-title":"Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE","volume":"70","author":"Werth","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib55","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/jac\/dkq184","article-title":"Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics","volume":"65","author":"Ulldemolins","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib56","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1177\/1060028014540610","article-title":"Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU","volume":"48","author":"Abdul-Aziz","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2019.11.001_bib57","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1128\/AAC.01232-08","article-title":"Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus","volume":"53","author":"Hughes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib58","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1128\/AAC.02624-14","article-title":"High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery","volume":"58","author":"Nesseler","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib59","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1128\/AAC.01410-06","article-title":"Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin","volume":"51","author":"Landersdorfer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.cmi.2019.11.001_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00806-19","article-title":"Cefazolin dosage adaptation in bacteremia and infective endocarditis based on a nomogram: a population pharmacokinetic study","volume":"63","author":"Bellouard","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.11.001_bib62","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib63","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/jac\/dkx140","article-title":"Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies","volume":"72","author":"Cojutti","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib64","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkr551","article-title":"Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration","volume":"67","author":"Wenisch","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2018.03.008","article-title":"Population pharmacokinetics of daptomycin in critically ill patients","volume":"52","author":"Soraluce","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib66","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/jac\/dky072","article-title":"Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review","volume":"73","author":"Foolad","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib67","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cmi.2019.03.030","article-title":"Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients","volume":"25","author":"Gutierrez-Gutierrez","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib68","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib69","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jac\/dkx453","article-title":"Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane\/tazobactam and comparators, and molecular epidemiology of carbapenemase producers","volume":"73","author":"Giani","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib70","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/IDR.S193638","volume":"12","author":"Liao","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2019.11.001_bib71","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/INF.0000000000001228","article-title":"Use of ceftolozane\/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient","volume":"35","author":"Aitken","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.11.001_bib72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40121-016-0104-3","article-title":"Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane\/tazobactam regimen","volume":"5","author":"Patel","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2019.11.001_bib73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s15010-017-1086-0","article-title":"Ceftolozane\/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant","volume":"46","author":"Peghin","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2019.11.001_bib74","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01637-19","article-title":"A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment","author":"Boulant","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib76","first-page":"61","article-title":"Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025744","article-title":"Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study","volume":"9","author":"Albasanz-Puig","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2019.11.001_bib78","article-title":"Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection\u2014a multi-site retrospective study","author":"Babich","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib79","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.cmi.2019.11.001_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00528-19","article-title":"Ceftazidime\/avibactam as salvage therapy for infections caused by Enterobacteriales co-resistant to carbapenems and polymyxins","volume":"63","author":"Guimaraes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib82","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Caston","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib83","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib85","first-page":"61","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib86","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib87","first-page":"61","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K.\u00a0pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime-avibactam in monotherapy or combination therapy against carbapenem resistant gram negative organisms: a meta-analysis","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib92","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2019.11.001_bib94","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01110-18","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib96","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diagmicrobio.2010.02.001","article-title":"Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes","volume":"67","author":"Nguyen","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib97","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.diagmicrobio.2010.10.013","article-title":"Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"69","author":"Neuner","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib98","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","article-title":"Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment","volume":"17","author":"Zarkotou","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib99","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K.\u00a0pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib101","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1586\/eri.12.138","article-title":"Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective","volume":"10","author":"Daikos","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2019.11.001_bib102","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib103","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dku168","article-title":"Combination therapy for carbapenem-resistant Gram-negative bacteria","volume":"69","author":"Paul","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib104","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of carbapenem-resistant klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib106","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.mayocp.2016.06.024","article-title":"A\u00a0predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae","volume":"91","author":"Gutierrez-Gutierrez","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2019.11.001_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01511-18","article-title":"Retrospective observational study from a Chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia","volume":"63","author":"Wang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib108","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib109","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02564-18","article-title":"A\u00a0combination antibiogram evaluation for pseudomonas aeruginosa in respiratory and blood sources from intensive care unit (ICU) and non-ICU settings in U.S. hospitals","volume":"63","author":"Puzniak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with Gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.11.001_bib111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cid\/cit223","article-title":"Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort","volume":"57","author":"Pena","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203295","article-title":"Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections","volume":"13","author":"Tschudin-Sutter","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2019.11.001_bib113","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","article-title":"Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment","volume":"25","author":"Piperaki","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.11.001_bib114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijantimicag.2018.10.020","article-title":"Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis","volume":"53","author":"Wang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijantimicag.2017.08.019","article-title":"Effect of combination therapy containing a high dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection","volume":"51","author":"Giannella","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib116","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.06389-11","article-title":"Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock","volume":"56","author":"Taccone","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib117","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/dkx330","article-title":"Maximally effective dosing regimens of meropenem in patients with septic shock","volume":"73","author":"Sjovall","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib118","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","article-title":"Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa","volume":"38","author":"Pilmis","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.11.001_bib119","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/jac\/dkx221","article-title":"Determination of alternative ceftolozane\/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg\/L","volume":"72","author":"Natesan","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib120","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1002\/phar.1744","article-title":"Ceftolozane\/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy","volume":"36","author":"Bremmer","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.11.001_bib121","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijantimicag.2016.06.005","article-title":"Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane\/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration","volume":"48","author":"Kuti","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.11.001_bib122","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13054-019-2434-5","article-title":"Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration","volume":"23","author":"Aguilar","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.11.001_bib123","first-page":"61","article-title":"Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.11.001_bib124","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/jac\/dkz103","article-title":"In\u00a0vivo pharmacokinetic analysis of meropenem\/vaborbactam during continuous venovenous haemodialysis","volume":"74","author":"Kufel","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19305932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19305932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:24:43Z","timestamp":1761117883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19305932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1198743X19305932"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.11.001","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the therapy of bacterial bloodstream infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}